MedPath

Levothyroxine

Generic Name
Levothyroxine
Brand Names
Eltroxin, Ermeza, Euthyrox, Levo-T, Levothroid, Levoxyl, Np Thyroid, Synthroid, Thyquidity, Tirosint, Unithroid
Drug Type
Small Molecule
Chemical Formula
C15H11I4NO4
CAS Number
51-48-9
Unique Ingredient Identifier
Q51BO43MG4

Overview

Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quantities of the thyroid hormones T (tetraiodothyronine or thyroxine) and T (triiodothyronine or Liothyronine), resulting in diminished down-stream effects of these hormones. Without sufficient quantities of circulating thyroid hormones, symptoms of hypothyroidism begin to develop such as fatigue, increased heart rate, depression, dry skin and hair, muscle cramps, constipation, weight gain, memory impairment, and poor tolerance to cold temperatures. In response to Thyroid Stimulating Hormone (TSH) release by the pituitary gland, a normally functioning thyroid gland will produce and secrete T, which is then converted through deiodination (by type I or type II 5′-deiodinases) into its active metabolite T. While T is the major product secreted by the thyroid gland, T exerts the majority of the physiological effects of the thyroid hormones; T and T have a relative potency of ~1:4 (T4:T3). T and T act on nearly every cell of the body, but have a particularly strong effect on the cardiac system. As a result, many cardiac functions including heart rate, cardiac output, and systemic vascular resistance are closely linked to thyroid status. Prior to the development of levothyroxine, Thyroid, porcine or desiccated thyroid, used to be the mainstay of treatment for hypothyroidism. However, this is no longer recommended for the majority of patients due to several clinical concerns including limited controlled trials supporting its use. Desiccated thyroid products contain a ratio of T4 to T3 of 4.2:1, which is significantly lower than the 14:1 ratio of secretion by the human thyroid gland. This higher proportion of T3 in desiccated thyroid products can lead to supraphysiologic levels of T3 which may put patients at risk of thyrotoxicosis if thyroid extract therapy is not adjusted according to the serum TSH.

Indication

Levothyroxine is indicated as replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. It is also indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Associated Conditions

  • Edematous Fibrosclerotic Panniculopathy (Cellulite)
  • Hypothyroidism
  • Localized Adiposity
  • Myxedema coma
  • Euthyroid Goitre
  • Thyrotropin dependent Well-Differentiated Thyroid Cancer

Research Report

Published: Jul 28, 2025

Levothyroxine (DB00451): A Comprehensive Monograph on its Pharmacology, Clinical Use, and Evolving Therapeutic Landscape

Section 1: Foundational Characteristics of Levothyroxine

This section establishes the fundamental identity of Levothyroxine, providing the chemical and physical context necessary for understanding its pharmacological behavior.

1.1. Chemical Identity and Physicochemical Properties

Levothyroxine is a synthetically manufactured small molecule drug, identified unequivocally by its Chemical Abstracts Service (CAS) Number 51-48-9 and its DrugBank accession number DB00451.[1] It is the levorotatory (L) stereoisomer of thyroxine (T4), the primary hormone synthesized and secreted by the thyroid gland.[1] This specific stereochemistry is paramount for its biological activity and receptor binding affinity.

The molecular structure of Levothyroxine is defined by the chemical formula C15​H11​I4​NO4​, corresponding to a molecular weight of approximately 776.87 g/mol.[1] Structurally, it is a tetraiodinated derivative of the amino acid tyrosine, featuring two phenyl rings linked by an ether oxygen. Each phenyl ring is substituted with two iodine atoms, which are critical for its hormonal function.[1] The precise chemical name, reflecting its structure and stereochemistry, is (2S)-2-Amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid.[5] Reflecting its long history and widespread use in clinical and research settings, Levothyroxine is known by an extensive list of synonyms, including L-T4, 3,3',5,5'-Tetraiodo-L-thyronine, and O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodo-L-tyrosine.[1]

Continue reading the full research report

Clinical Trials

View More Clinical Trials

Sign in to access the complete clinical trial database with detailed study information.

Title
Posted
Study ID
Phase
Status
Sponsor
2023/09/14
Phase 3
Completed
2023/04/21
Phase 2
Completed
2023/04/07
Phase 2
Completed
2023/02/03
Phase 2
Active, not recruiting
2022/09/02
Phase 2
Recruiting
2022/06/09
Phase 2
Completed
2022/05/23
N/A
Completed
OMER B ABDELBASIT
2022/05/12
Phase 4
Completed
Federico II University
2022/04/07
Phase 3
Recruiting
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
2022/03/11
N/A
Recruiting

FDA Drug Approvals

View More FDA Approvals

Sign in to access additional FDA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
A-S Medication Solutions
50090-6880
ORAL
0.112 mg in 1 1
11/8/2023
Mylan Pharmaceuticals Inc.
0378-1811
ORAL
112 ug in 1 1
8/31/2020
Mylan Pharmaceuticals Inc.
0378-1800
ORAL
25 ug in 1 1
8/31/2020
NorthStar RxLLC
72603-664
ORAL
100 ug in 1 1
4/15/2025
REMEDYREPACK INC.
70518-3208
ORAL
50 ug in 1 1
6/2/2025
Major Pharmaceuticals
0904-6956
ORAL
0.15 mg in 1 1
2/4/2020
IBSA Pharma Inc.
71858-0105
ORAL
13 ug in 1 mL
11/30/2023
Bryant Ranch Prepack
63629-2094
ORAL
300 ug in 1 1
7/23/2020
A-S Medication Solutions
50090-5661
ORAL
50 ug in 1 1
7/23/2020
NuCare Pharmaceuticals,Inc.
68071-4866
ORAL
100 ug in 1 1
2/17/2021

EMA Drug Approvals

View More EMA Approvals

Sign in to access additional EMA-approved drug information with detailed regulatory data.

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

View More HSA Approvals

Sign in to access additional HSA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

View More NMPA Approvals

Sign in to access additional NMPA-approved drug information with detailed regulatory data.

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

View More PPB Approvals

Sign in to access additional PPB-approved drug information with detailed regulatory data.

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

Health Canada Drug Approvals

View More Health Canada Approvals

Sign in to access additional Health Canada approved drug information with detailed regulatory data.

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
APO-LEVOTHYROXINE
02550741
Tablet - Oral
112 MCG
3/17/2025
TIROCAP
02508516
Capsule - Oral
75 MCG
N/A
APO-LEVOTHYROXINE
02550733
Tablet - Oral
88 MCG
3/17/2025
TIROCAP
02508583
Capsule - Oral
175 MCG
N/A
TIROCAP
02508567
Capsule - Oral
137 MCG
N/A
SYNTHROID
BGP Pharma ULC
02172119
Tablet - Oral
125 MCG
12/31/1996
LEVOTHYROXINE SODIUM FOR INJECTION
avir pharma inc.
02461714
Powder For Solution - Intramuscular ,  Intravenous
200 MCG / VIAL
11/15/2019
LEVOTEC 175MCG TABLETS USP
technilab pharma inc.
02237220
Tablet - Oral
175 MCG / TAB
9/8/1998
SYNTHROID TAB 88MCG USP
boots pharmaceuticals ltd.
01980963
Tablet - Oral
88 MCG
12/31/1993
SYNTHROID TAB 112MCG USP
boots pharmaceuticals ltd.
01980947
Tablet - Oral
112 MCG
12/31/1993

CIMA AEMPS Drug Approvals

View More CIMA AEMPS Approvals

Sign in to access additional CIMA AEMPS approved drug information with detailed regulatory data.

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

View More Philippines FDA Approvals

Sign in to access additional Philippines FDA approved drug information with detailed regulatory data.

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

View More Saudi SFDA Approvals

Sign in to access additional Saudi SFDA approved drug information with detailed regulatory data.

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

View More Malaysia NPRA Approvals

Sign in to access additional Malaysia NPRA approved drug information with detailed regulatory data.

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

View More UK EMC Drug Information

Sign in to access additional UK EMC drug information with detailed pharmaceutical data.

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.